Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
Mallinckrodt
Merck
AstraZeneca

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR CELEXA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Celexa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018902 ↗ Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) Completed National Institute of Mental Health (NIMH) Phase 2/Phase 3 2001-01-01 The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
NCT00018902 ↗ Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) Completed University of Pittsburgh Phase 2/Phase 3 2001-01-01 The purpose of the study is to determine how best to treat adolescents with depression that is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy.
NCT00044798 ↗ Magnetic Stimulation Therapy for Treating Vascular Depression Completed National Institute of Mental Health (NIMH) Phase 3 2001-09-01 This 12-week study will evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) of the brain, followed by citalopram (Celexa┬«), for treatment of depression associated with small vascular lesions in the brain (vascular depression).
NCT00044798 ↗ Magnetic Stimulation Therapy for Treating Vascular Depression Completed University of Iowa Phase 3 2001-09-01 This 12-week study will evaluate the effectiveness of repetitive transcranial magnetic stimulation (rTMS) of the brain, followed by citalopram (Celexa┬«), for treatment of depression associated with small vascular lesions in the brain (vascular depression).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Celexa

Condition Name

Condition Name for Celexa
Intervention Trials
Depression 11
Major Depressive Disorder 11
Healthy 4
Anxiety Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Celexa
Intervention Trials
Depression 29
Depressive Disorder 24
Depressive Disorder, Major 15
Disease 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Celexa

Trials by Country

Trials by Country for Celexa
Location Trials
United States 105
Canada 6
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Celexa
Location Trials
California 14
New York 13
Pennsylvania 9
Massachusetts 8
Ohio 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Celexa

Clinical Trial Phase

Clinical Trial Phase for Celexa
Clinical Trial Phase Trials
Phase 4 14
Phase 3 5
Phase 2/Phase 3 3
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Celexa
Clinical Trial Phase Trials
Completed 46
Withdrawn 3
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Celexa

Sponsor Name

Sponsor Name for Celexa
Sponsor Trials
National Institute of Mental Health (NIMH) 24
New York State Psychiatric Institute 7
University of Pittsburgh 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Celexa
Sponsor Trials
Other 51
NIH 33
Industry 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Medtronic
Dow
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.